Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinoic acid capsules plus toripalimab in advanced unresectable or metastatic melanoma
ChiCTR2400087686Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tretinoin and toripalimab in cutaneous melanoma (CM) and acral lentiginous melanoma (ALM), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tretinointoripalimab
03
Conditions
cutaneous melanoma (CM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2400087686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087686.